Investor Presentaiton

Established IBD presence with Zeposia in UC, with potential expansion to Crohn's Disease Zeposia in IBD Ulcerative Colitis Approved in the U.S. & EU Zeposia provides UC patients with efficacy comparable to biologics, and a favorable safety profile in an oral medicine Primary endpoints: • Induction studies: Week 12 clinical remission • Maintenance study: Co primary @ Week 52 Crohn's Disease Phase 3 YELLOWSTONE program ongoing Maintenance study data anticipated 2026 Study 32011 N = 400 Zeposia N = 200 Placebo N = 400 Zeposia clinical remission Study 32022 N = 200 Placebo and endoscopic response 12 wk induction study Ill Bristol Myers Squibb™ 1. NCT03440372; 2. NCT03440385; 3. NCT03464097 Zeposia responders or remitters are re-randomized 1:1 to Zeposia or Placebo Zeposia Placebo 52 wk maintenance study³ Not for Product Promotional Use 154

View entire presentation